Risk	risk	O	O	O	O
for	for	O	O	O	O
valvular	valvular	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
among	among	O	O	O	O
users	users	O	O	O	O
of	of	O	O	O	O
fenfluramine	fenfluramine	O	O	OTHERS	I
and	and	O	O	O	O
dexfenfluramine	dexfenfluramine	O	O	OTHERS	I
who	who	O	O	O	O
underwent	underwent	O	O	O	O
echocardiography	echocardiography	O	O	O	O
before	before	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
medication	medication	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Because	because	O	O	O	O
uncontrolled	uncontrolled	O	O	O	O
echocardiographic	echocardiographic	O	O	O	O
surveys	surveys	O	O	O	O
suggested	suggested	O	O	O	O
that	that	O	O	O	O
up	up	O	O	O	O
to	to	O	O	O	O
30	30	O	O	O	O
%	%	O	O	O	O
to	to	O	O	O	O
38	38	O	O	O	O
%	%	O	O	O	O
of	of	O	O	O	O
users	users	O	O	O	O
of	of	O	O	O	O
fenfluramine	fenfluramine	O	O	OTHERS	I
and	and	O	O	O	O
dexfenfluramine	dexfenfluramine	O	O	OTHERS	I
had	had	O	O	O	O
valvular	valvular	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
,	,	O	O	O	O
these	these	O	O	O	O
drugs	drugs	O	O	O	O
were	were	O	O	O	O
withdrawn	withdrawn	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
market	market	O	O	O	O
.	.	O	O	O	O

OBJECTIVE	objective	O	O	O	O
:	:	O	O	O	O
To	to	O	O	O	O
determine	determine	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
for	for	O	O	O	O
new	new	O	O	O	O
or	or	O	O	O	O
worsening	worsening	O	O	O	O
valvular	valvular	O	O	OTHERS	I
abnormalities	abnormalities	O	O	OTHERS	I
among	among	O	O	O	O
users	users	O	O	O	O
of	of	O	O	O	O
fenfluramine	fenfluramine	O	O	OTHERS	I
or	or	O	O	O	O
dexfenfluramine	dexfenfluramine	O	O	OTHERS	I
who	who	O	O	O	O
underwent	underwent	O	O	O	O
echocardiography	echocardiography	O	O	O	O
before	before	O	O	O	O
they	they	O	O	O	O
began	began	O	O	O	O
to	to	O	O	O	O
take	take	O	O	O	O
these	these	O	O	O	O
medications	medications	O	O	O	O
.	.	O	O	O	O

DESIGN	design	O	O	O	O
:	:	O	O	O	O
Cohort	cohort	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

SETTING	setting	O	O	O	O
:	:	O	O	O	O
Academic	academic	O	O	O	O
primary	primary	O	O	O	O
care	care	O	O	O	O
practices	practices	O	O	O	O
.	.	O	O	O	O

PATIENTS	patients	O	O	O	O
:	:	O	O	O	O
46	46	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
used	used	O	O	O	O
fenfluramine	fenfluramine	O	O	OTHERS	I
or	or	O	O	O	O
dexfenfluramine	dexfenfluramine	O	O	OTHERS	I
for	for	O	O	O	O
14	14	O	O	O	O
days	days	O	O	O	O
or	or	O	O	O	O
more	more	O	O	O	O
and	and	O	O	O	O
had	had	O	O	O	O
echocardiograms	echocardiograms	O	O	O	O
obtained	obtained	O	O	O	O
before	before	O	O	O	O
therapy	therapy	O	O	O	O
.	.	O	O	O	O

MEASUREMENTS	measurements	O	O	O	O
:	:	O	O	O	O
Follow-up	follow-up	O	O	O	O
echocardiography	echocardiography	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
primary	primary	O	O	O	O
outcome	outcome	O	O	O	O
was	was	O	O	O	O
new	new	O	O	O	O
or	or	O	O	O	O
worsening	worsening	O	O	O	O
valvulopathy	valvulopathy	O	O	OTHERS	I
,	,	O	O	O	O
defined	defined	O	O	O	O
as	as	O	O	O	O
progression	progression	O	O	O	O
of	of	O	O	O	O
either	either	O	O	O	O
aortic	aortic	O	O	O	O
or	or	O	O	O	O
mitral	mitral	O	DISEASE	OTHERS	I
regurgitation	regurgitation	O	DISEASE	OTHERS	I
by	by	O	O	O	O
at	at	O	O	O	O
least	least	O	O	O	O
one	one	O	O	O	O
degree	degree	O	O	O	O
of	of	O	O	O	O
severity	severity	O	O	O	O
and	and	O	O	O	O
disease	disease	O	O	O	O
that	that	O	O	O	O
met	met	O	O	O	O
U.S.	u.s.	O	O	O	O
Food	food	O	O	O	O
and	and	O	O	O	O
Drug	drug	O	O	O	O
Administration	administration	O	O	O	O
criteria	criteria	O	O	O	O
(	(	O	O	O	O
at	at	O	O	O	O
least	least	O	O	O	O
mild	mild	O	O	O	O
aortic	aortic	O	O	OTHERS	I
regurgitation	regurgitation	O	O	OTHERS	I
or	or	O	O	O	O
moderate	moderate	O	O	O	O
mitral	mitral	O	DISEASE	OTHERS	I
regurgitation	regurgitation	O	DISEASE	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Two	two	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
4.3	4.3	O	O	O	O
%	%	O	O	O	O
[	[	O	O	O	O
95	95	O	O	O	O
%	%	O	O	O	O
CI	ci	O	O	O	O
,	,	O	O	O	O
0.6	0.6	O	O	O	O
%	%	O	O	O	O
to	to	O	O	O	O
14.8	14.8	O	O	O	O
%	%	O	O	O	O
]	]	O	O	O	O
)	)	O	O	O	O
receiving	receiving	O	O	O	O
fenfluramine-phentermine	fenfluramine-phentermine	O	O	O	O
developed	developed	O	O	O	O
valvular	valvular	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

One	one	O	O	O	O
had	had	O	O	O	O
baseline	baseline	O	O	O	O
bicuspid	bicuspid	O	DISEASE	OTHERS	I
aortic	aortic	O	DISEASE	OTHERS	I
valve	valve	O	DISEASE	OTHERS	I
and	and	O	O	O	O
mild	mild	O	O	O	O
aortic	aortic	O	O	OTHERS	I
regurgitation	regurgitation	O	O	OTHERS	I
that	that	O	O	O	O
progressed	progressed	O	O	O	O
to	to	O	O	O	O
moderate	moderate	O	O	O	O
regurgitation	regurgitation	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
second	second	O	O	O	O
patient	patient	O	O	O	O
developed	developed	O	O	O	O
new	new	O	O	O	O
moderate	moderate	O	O	O	O
aortic	aortic	O	O	OTHERS	I
insufficiency	insufficiency	O	O	OTHERS	I
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
Users	users	O	O	O	O
of	of	O	O	O	O
diet	diet	O	O	O	O
medications	medications	O	O	O	O
are	are	O	O	O	O
at	at	O	O	O	O
risk	risk	O	O	O	O
for	for	O	O	O	O
valvular	valvular	O	DISEASE	OTHERS	I
heart	heart	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
incidence	incidence	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
lower	lower	O	O	O	O
than	than	O	O	O	O
that	that	O	O	O	O
reported	reported	O	O	O	O
previously	previously	O	O	O	O
.	.	O	O	O	O

